NewcelX Ltd.
NCEL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.93M
Close$
$0.48
81.2% downside
Current Fair Value
81.2% downsideOvervalued by 81.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $14.93 Million |
|---|---|
| Enterprise Value | $14.62 Million |
| Earnings per Share | $-2.16 |
| Beta | 0.93 |
| Outstanding Shares | 5,856,314 |
Return
| Return on Equity | -11.92% |
|---|---|
| Return on Assets | -7.42% |
| Return on Invested Capital | -126.77% |
Valuation & Multiples
| P/E Ratio | 7.73 |
|---|---|
| PEG | 25.26 |
| Price to Sales | - |
| Price to Book Ratio | 2.55 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.91 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-0.53
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.65
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.31% |
|---|---|
| Total Invested | $31▼ 99.93% |
| Investors Holding | 1▼ 3.00% |
About NLS Pharmaceutics Ltd
4 employees
CEO: Ronen Twito
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system d...